» Articles » PMID: 38483655

Antitumoral Activity of Cecropia Pachystachya Leaves Extract in Vitro and in Vivo Model of Rat Glioma: Brain and Blood Effects

Abstract

The aim of this study was to investigate the antiglioma effect of Cecropia pachystachya Trécul (CEC) leaves extract against C6 and U87 glioblastoma (GB) cells and in a rat preclinical GB model. The CEC extract reduced in vitro cell viability and biomass. In vivo, the extract decreased the tumor volume approximately 62%, without inducing systemic toxicity. The deficit in locomotion and memory and an anxiolytic-like behaviors induced in the GB model were minimized by CEC. The extract decreased the levels of reactive oxygen species, nitrites and thiobarbituric acid reactive substances and increased the activity of antioxidant enzymes in platelets, sera and brains of GB animals. The activity of NTPDases, 5'-nucleotidase and adenosine deaminase (ADA) was evaluated in lymphocytes, platelets and serum. In platelets, ATP and AMP hydrolysis was reduced and hydrolysis of ADP and the activity of ADA were increased in the control, while in CEC-treated animals no alteration in the hydrolysis of ADP was detected. In serum, the reduction in ATP hydrolysis was reversed by CEC. In lymphocytes, the increase in the hydrolysis of ATP, ADP and in the activity of ADA observed in GB model was altered by CEC administration. The observed increase in IL-6 and decrease in IL-10 levels in the serum of GB animals was reversed by CEC. These results demonstrate that CEC extract is a potential complementary treatment to GB, decreasing the tumor size, while modulating aspects of redox and purinergic systems.

Citing Articles

Antitumor Effect of Butia odorata Hydroalcoholic Extract on C6 and U87MG Glioma Cell Lines: Impact on Redox Status and Inflammation Signaling.

Saraiva J, Dos Santos F, Bona N, da Silveira L, Simoes W, da Silva G Neurochem Res. 2024; 50(1):56.

PMID: 39671046 DOI: 10.1007/s11064-024-04305-7.

References
1.
Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

2.
Caragher S, Chalmers A, Gomez-Roman N . Glioblastoma's Next Top Model: Novel Culture Systems for Brain Cancer Radiotherapy Research. Cancers (Basel). 2019; 11(1). PMC: 6356812. DOI: 10.3390/cancers11010044. View

3.
Grochans S, Cybulska A, Siminska D, Korbecki J, Kojder K, Chlubek D . Epidemiology of Glioblastoma Multiforme-Literature Review. Cancers (Basel). 2022; 14(10). PMC: 9139611. DOI: 10.3390/cancers14102412. View

4.
Fang X, Wang C, Balgley B, Zhao K, Wang W, He F . Targeted tissue proteomic analysis of human astrocytomas. J Proteome Res. 2012; 11(8):3937-46. PMC: 3413268. DOI: 10.1021/pr300303t. View

5.
Abbas M, Kausar S, Cui H . Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterations. Clin Transl Oncol. 2019; 22(7):963-977. DOI: 10.1007/s12094-019-02227-3. View